Taho Pharmaceuticals (ROCO:6467) 5-Year Yield-on-Cost %: 0.00 (As of Aug. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6467 Taho Pharmaceuticals Ltd ROCO:6467
34 GF Score
Price NT$140.50
! 2 Warning Signs
View Full Analysis

What is Taho Pharmaceuticals 5-Year Yield-on-Cost %?

Taho Pharmaceuticals ROCO:6467 +0.72% 34 5-Year Yield-on-Cost % is 0.00 as of Aug. 23, 2026. GuruFocus rates ROCO:6467 with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 507 Drug Manufacturers companies, Taho Pharmaceuticals ranks worse than 197238.46% on this metric.

Taho Pharmaceuticals's yield on cost for the quarter that ended in Dec. 2025 was 0.00.


The historical rank and industry rank for Taho Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:



ROCO:6467's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.36
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Taho Pharmaceuticals  (ROCO:6467) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Taho Pharmaceuticals 5-Year Yield-on-Cost % Related Terms

ROCO:6467 vs ZTS: 5-Year Yield-on-Cost % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Taho Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Taho Pharmaceuticals 5-Year Yield-on-Cost % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taho Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Taho Pharmaceuticals's 5-Year Yield-on-Cost % falls into.


ROCO:6467
34GF Score
Taho Pharmaceuticals Ltd ROCO:6467
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taho Pharmaceuticals 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Taho Pharmaceuticals is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Taho Pharmaceuticals (ROCO:6467) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 23, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Taho Pharmaceuticals and its competitors. According to the industry distribution chart, Taho Pharmaceuticals ranks #999999 out of 507 companies in the Drug Manufacturers industry.
Is Taho Pharmaceuticals' 5-Year Yield-on-Cost % too high?
Taho Pharmaceuticals' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Taho Pharmaceuticals ranks #999999 out of 507 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Taho Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Taho Pharmaceuticals' 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Taho Pharmaceuticals ranks #999999 out of 507 companies for 5-Year Yield-on-Cost %. This places Taho Pharmaceuticals in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.36, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Taho Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taho Pharmaceuticals's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taho Pharmaceuticals stock overvalued right now?
Taho Pharmaceuticals (ROCO:6467) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Taho Pharmaceuticals' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Taho Pharmaceuticals (ROCO:6467), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Taho Pharmaceuticals Business Description

Address No. 550, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN
Taho Pharmaceuticals Ltd is a Taiwan based company focused on identifying and developing new products that offer therapeutic options to patient populations that may be under served. It offers a transdermal delivery platform that allows the active ingredient to be absorbed by the skin and distributed through the bloodstream. Its transmucosal delivery system delivers the drug as a thin film, an evolution from tablets or capsules. The company is conducting research and development of multiple new drugs using two different drug delivery platform technologies: transdermal and transmucosal.
34GF Score

Get the complete analysis for ROCO:6467

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$140.50
Price